Literature DB >> 20936978

Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions.

Bryan P Danielson1, Gustavo E Ayala, Jason T Kimata.   

Abstract

BACKGROUND: There are questions regarding the prevalence of xenotropic murine leukemia virus-related virus (XMRV) in patients with prostate cancer and its association with the RNASEL R462Q polymorphism. We therefore investigated whether XMRV infection could be found in patients with prostate cancer from the southern United States, and we sought to verify the association with the R462Q.
METHODS: Prostate tissue specimens of 144 patients with prostate cancer from the southern United States were genotyped for R462Q by real time polymerase chain reaction allelic discrimination and were screened for XMRV proviral DNA by nested polymerase chain reaction specific for the env gene.
RESULTS: The R462Q polymorphism was found at an allelic frequency of 0.33. XMRV was detected in 32 (22%) of the 144 patients. Patients were significantly more likely to test positive for XMRV in both tumor and normal tissue rather than either alone (κ = 0.64). A positive result for XMRV was not significantly correlated with the R462Q polymorphism (P = .82) or clinical pathological parameters of prostate cancer, including Gleason score (P = .29).
CONCLUSIONS: XMRV is detectable in normal and tumor prostate tissue from patients with prostate cancer, independent of R462Q. The presence of XMRV in normal tissue suggests that infection may precede cancer onset.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20936978      PMCID: PMC3058280          DOI: 10.1086/656146

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer.

Authors:  Annika Rökman; Tarja Ikonen; Eija H Seppälä; Nina Nupponen; Ville Autio; Nina Mononen; Joan Bailey-Wilson; Jeffrey Trent; John Carpten; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Olli-P Kallioniemi; Johanna Schleutker
Journal:  Am J Hum Genet       Date:  2002-04-08       Impact factor: 11.025

2.  A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.

Authors:  Stéphane Guindon; Olivier Gascuel
Journal:  Syst Biol       Date:  2003-10       Impact factor: 15.683

3.  RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.

Authors:  Graham Casey; Phillippa J Neville; Sarah J Plummer; Ying Xiang; Lisa M Krumroy; Eric A Klein; William J Catalona; Nina Nupponen; John D Carpten; Jeffrey M Trent; Robert H Silverman; John S Witte
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

4.  Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Truong D Dang; Gustavo E Ayala; David R Rowley
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

Review 5.  Reactive stroma in prostate cancer progression.

Authors:  J A Tuxhorn; G E Ayala; D R Rowley
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

6.  An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.

Authors:  Beihua Dong; Sanggu Kim; Seunghee Hong; Jaydip Das Gupta; Krishnamurthy Malathi; Eric A Klein; Don Ganem; Joseph L Derisi; Samson A Chow; Robert H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-18       Impact factor: 11.205

7.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

Authors:  Jennifer A Tuxhorn; Gustavo E Ayala; Megan J Smith; Vincent C Smith; Truong D Dang; David R Rowley
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

8.  Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.

Authors:  Gustavo Ayala; Jennifer A Tuxhorn; Thomas M Wheeler; Anna Frolov; Peter T Scardino; Makoto Ohori; Marcus Wheeler; Jeffrey Spitler; David R Rowley
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

9.  Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium.

Authors:  A F Olumi; G D Grossfeld; S W Hayward; P R Carroll; T D Tlsty; G R Cunha
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

10.  Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

Authors:  Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi
Journal:  PLoS Pathog       Date:  2006-03-31       Impact factor: 6.823

View more
  42 in total

1.  NF-kappaB activation stimulates transcription and replication of retrovirus XMRV in human B-lineage and prostate carcinoma cells.

Authors:  Shuhei Sakakibara; Kaori Sakakibara; Giovanna Tosato
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 2.  Xenotropic Murine Leukemia Virus-Related Virus (XMRV) and the Safety of the Blood Supply.

Authors:  Andrew D Johnson; Claudia S Cohn
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

Review 3.  Is XMRV a causal virus for prostate cancer?

Authors:  Zhen-Zhen Zhang; Bao-Feng Guo; Zhuang Feng; Ling Zhang; Xue-Jian Zhao
Journal:  Asian J Androl       Date:  2011-07-18       Impact factor: 3.285

Review 4.  Recombinant origin, contamination, and de-discovery of XMRV.

Authors:  Krista Delviks-Frankenberry; Oya Cingöz; John M Coffin; Vinay K Pathak
Journal:  Curr Opin Virol       Date:  2012-07-19       Impact factor: 7.090

5.  In vivo hypermutation of xenotropic murine leukemia virus-related virus DNA in peripheral blood mononuclear cells of rhesus macaque by APOBEC3 proteins.

Authors:  Ao Zhang; Hal Bogerd; Francois Villinger; Jaydip Das Gupta; Beihua Dong; Eric A Klein; John Hackett; Gerald Schochetman; Bryan R Cullen; Robert H Silverman
Journal:  Virology       Date:  2011-10-06       Impact factor: 3.616

6.  Retraction for Schlaberg et al., XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.

Authors:  Robert Schlaberg; Daniel J Choe; Kristy R Brown; Harshwardhan M Thaker; Ila R Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

7.  Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types.

Authors:  Ning Tang; Andrea Frank; Gregor Leckie; John Hackett; Graham Simmons; Michael Busch; Klara Abravaya
Journal:  J Virol Methods       Date:  2011-10-25       Impact factor: 2.014

8.  The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans.

Authors:  Graham Simmons; Simone A Glynn; Jerry A Holmberg; John M Coffin; Indira K Hewlett; Shyh-Ching Lo; Judy A Mikovits; William M Switzer; Jeffrey M Linnen; Michael P Busch
Journal:  Transfusion       Date:  2011-03-01       Impact factor: 3.157

9.  Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer.

Authors:  Faraz Ahmed Baig; Talat Mirza; Amna Hamid; Serajuddaula Syed; Qamar Jamal
Journal:  Turk J Urol       Date:  2017-07-31

Review 10.  Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses.

Authors:  Zhi-Ming Zheng
Journal:  Int J Biol Sci       Date:  2010-12-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.